Helping allergy antibodies let go of immune cells faster
Accelerated dissociation of IgE receptor complexes
Trying antibody-based tools to quickly remove IgE from immune cells so people with allergies may become less reactive to allergens.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11144459 on NIH RePORTER |
What this research studies
Researchers are creating special antibody-based molecules that latch onto two parts of the IgE-receptor complex to make allergy antibodies release from immune cells faster. They will make and test new bispecific anti-IgE antibodies and hybrid IgG/DARPin molecules to rapidly dismantle IgE:FceRI complexes on mast cells and basophils. The team will also evolve higher-affinity versions of the CD23 receptor and isolate new anti-FceRIα antibodies using yeast display and structural studies to learn how these interactions control IgE behavior. Most work is lab-based but is aimed at producing reagents and knowledge that could lead to patient-focused therapies or sample-based clinical work in the future.
Who could benefit from this research
Good fit: People with IgE-mediated allergic conditions (for example severe allergies, allergic asthma, or food allergies) or those willing to donate blood or tissue samples for research would be most relevant.
Not a fit: Individuals whose conditions are not driven by IgE-mediated allergy or those seeking immediate, approved treatments are unlikely to get direct benefit from this primarily laboratory-focused project.
Why it matters
Potential benefit: Could lead to faster desensitization approaches and new treatments that reduce allergic reactions or potentially harness IgE biology for therapies like cancer immunotherapy.
How similar studies have performed: Prior laboratory work has shown bispecific molecules can destabilize IgE:FceRI complexes, but moving this approach into clinical use remains early and experimental.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Jardetzky, Theodore S — Stanford University
- Study coordinator: Jardetzky, Theodore S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.